ReviewCancer biology & therapy2025
Copper death combination therapy: the innovative frontier and challenges in prostate cancer treatment.
Review in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Review
- Review
- Synergistic anticancer effects of cabozantinib and cuproptosis induction driven by DHRS2-KAT2A-H3K27ac axis in clear cell renal cell carcinoma.Biology direct · 2026Article
- Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy.Frontiers in oncology · 2026Review
- Epigenetic regulation of cuproptosis in cancer: mechanisms, microenvironment, and therapeutic implications.Frontiers in cell and developmental biology · 2026Review
- Epigenetic modification of cuproptosis by non-coding RNAs in cancer drug resistance.Molecular cancer · 2025Review
- Hyperbranched Polyethyleneimine-Coordinated Copper(II) Metallopolymers with Preferential Targeting to Prostate Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques.Stem cells international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCA) remains a significant health challenge, necessitating the exploration of novel therapeutic strategies to enhance patient outcomes. Recent research has identified cuproptosis, a copper-dependent programmed cell death mechanism, as a promising target in PCA treatment. Elevated copper levels have been associated with tumor progression and therapeutic resistance, highlighting the need for innovative approaches. This review synthesizes current findings on the role of copper and cuproptosis in PCA, focusing on the mechanisms underlying cuproptosis, the identification of key biomarkers, and the therapeutic potential of copper complexes and ionophores. The integration of cuproptosis-related biomarkers into clinical practice may facilitate personalized treatment strategies, while ongoing research into copper-based therapies holds promise for overcoming limitations of traditional chemotherapy. Future directions should emphasize elucidating the molecular mechanisms of cuproptosis and optimizing therapeutic applications to improve patient outcomes in PCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.